These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Technology: Barriers to misuse. Dolgin E Nature; 2015 Jun; 522(7557):S60-1. PubMed ID: 26107099 [No Abstract] [Full Text] [Related]
6. Abuse deterrence focus of upcoming opioid formulations. Lavine G Am J Health Syst Pharm; 2008 Mar; 65(5):381, 385. PubMed ID: 18281726 [No Abstract] [Full Text] [Related]
7. The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study. Larance B; Dobbins T; Peacock A; Ali R; Bruno R; Lintzeris N; Farrell M; Degenhardt L Lancet Psychiatry; 2018 Feb; 5(2):155-166. PubMed ID: 29336948 [TBL] [Abstract][Full Text] [Related]
8. A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamper-resistant formulation of controlled-release oxycodone. Peacock A; Degenhardt L; Larance B; Cama E; Lintzeris N; Ali R; Bruno R Pharmacoepidemiol Drug Saf; 2015 Dec; 24(12):1321-33. PubMed ID: 26419615 [TBL] [Abstract][Full Text] [Related]
9. Opioid use following the introduction of an extended-release oxycodone formulation with tamper-resistant properties: Prospective historical chart review in methadone-maintained patients. Sankey C; Setnik B; Harsanyi Z; Michalko K; Yang Z; Geoffroy P J Opioid Manag; 2016; 12(2):149-59. PubMed ID: 27194200 [TBL] [Abstract][Full Text] [Related]
10. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin. Cicero TJ; Ellis MS JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692 [TBL] [Abstract][Full Text] [Related]
11. Opioid rain: opioid prescribing is growing and practice is diverging. Davis A; Davis K; Gerard C; Goyal S; Jackson G; James C; Loe E; Nicolls B; O'Rourke MA; Shuker C; Te Karu L N Z Med J; 2016 Aug; 129(1440):11-7. PubMed ID: 27538034 [No Abstract] [Full Text] [Related]
12. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol. Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480 [TBL] [Abstract][Full Text] [Related]
13. Person-level changes in oxycodone use after the introduction of a tamper-resistant formulation in Australia. Schaffer AL; Buckley NA; Degenhardt L; Larance B; Cairns R; Dobbins TA; Pearson SA CMAJ; 2018 Mar; 190(12):E355-E362. PubMed ID: 29581162 [TBL] [Abstract][Full Text] [Related]
14. Drug Formulation Advances in Extended-Release Medications for Pain Control. Jones MR; Carney MJ; Kaye RJ; Prabhakar A; Kaye AD Curr Pain Headache Rep; 2016 Jun; 20(6):36. PubMed ID: 27084375 [TBL] [Abstract][Full Text] [Related]
15. Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States. Kirson NY; Shei A; White AG; Birnbaum HG; Ben-Joseph R; Rossiter LF; Michna E Pain Med; 2014 Sep; 15(9):1450-4. PubMed ID: 25041231 [No Abstract] [Full Text] [Related]
16. The impact of OxyContin reformulation at the Sydney Medically Supervised Injecting Centre: Pros and cons. Jauncey M; Livingston M; Salmon AM; Dietze P Int J Drug Policy; 2018 Mar; 53():17-22. PubMed ID: 29268238 [No Abstract] [Full Text] [Related]